Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics宣佈了一項新的美國專利，該專利涵蓋了左旋西門丹在心力衰竭肺動脈高壓中的使用，同時保持射血分數，新專利爲2040年12月提供保護
Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics宣佈了一項新的美國專利，該專利涵蓋了左旋西門丹在心力衰竭肺動脈高壓中的使用，同時保持射血分數，新專利爲2040年12月提供保護
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。